@article{2e14ef0ab70d41b9bea7b6907e2c731a,
title = "Blood and Cerebrospinal Fluid Biomarkers in Vascular Dementia and Alzheimer's Disease: A Brief Review",
keywords = "Amyloid beta (Aβ), Biomarkers, Blood, Cerebrospinal fluid (CSF), Tau",
author = "Gorelick, {Philip B.}",
note = "Funding Information: MARKVCID includes seven original research sites and a coordinating center funded by grants from the US National Institute of Neurological Disorders and Stroke, National Institute on Aging, and BrightFocus Foundation. 14 The initiative is largely focused on SSVD, the most common phenotype of VCI. The initial 5-year mission of the study is to analyze and optimize candidate VCI and dementia biomarkers in years 1 to 2 and develop and carryout a biomarker scaling up, multisite protocol and validation in years 3 to 5. 14 To achieve the goals of the study, the following protocols or procedures have been established: clinical/cognitive measure collection manuals; biospecimen collection best practices; imaging standard operating procedures; patient MRI protocols; phantom MRI protocols; imaging-based biomarker kit protocols; and fluid-based biomarker kit protocols. 14 ",
year = "2023",
month = feb,
doi = "10.1016/j.cger.2022.08.001",
language = "English (US)",
volume = "39",
pages = "67--76",
journal = "Clinics in Geriatric Medicine",
issn = "0749-0690",
publisher = "W.B. Saunders Ltd",
number = "1",
}